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Variable Impact on Mortality of AIDS-Deﬁning
Events Diagnosed during Combination Antiretroviral
Therapy: Not All AIDS-Deﬁning Conditions Are
Created Equal
Antiretroviral Therapy Cohort Collaboration (ART-CC)
a
Background. The extent to which mortality differs following individual acquired immunodeﬁciency syndrome
(AIDS)–deﬁning events (ADEs) has not been assessed among patients initiating combination antiretroviraltherapy.
Methods. We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral
therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE thatoccurred
in 150 patients, after stratiﬁcation by cohort and adjustment for sex, HIV transmission group, number of anti-
retroviral drugs initiated, regimen, age, date of starting combination antiretroviral therapy, and CD4
+ cell count
and HIV RNA load at initiation of combination antiretroviral therapy. ADEs that occurred in !50 patients were
grouped together to form a “rare ADEs” category.
Results. During a median follow-up period of 43 months (interquartile range, 19–70 months), 2880 ADEs
were diagnosed in 2262 patients; 1146 patients died. The most common ADEs were esophageal candidiasis (in
360 patients), Pneumocystis jiroveci pneumonia (320 patients), and Kaposi sarcoma (308 patients). The greatest
mortality hazard ratio was associated with non-Hodgkin’s lymphoma (hazard ratio, 17.59; 95% conﬁdence interval,
13.84–22.35) and progressive multifocal leukoencephalopathy (hazard ratio, 10.0; 95% conﬁdence interval, 6.70–
14.92). Three groups of ADEs were identiﬁed on the basis of the ranked hazard ratios with bootstrapped conﬁdence
intervals: severe (non-Hodgkin’s lymphoma and progressive multifocal leukoencephalopathy [hazard ratio, 7.26;
95% conﬁdence interval, 5.55–9.48]), moderate (cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex,
disseminated Mycobacterium avium complex, and rare ADEs [hazard ratio, 2.35; 95% conﬁdence interval, 1.76–
3.13]), and mild (all other ADEs [hazard ratio, 1.47; 95% conﬁdence interval, 1.08–2.00]).
Conclusions. In the combination antiretroviral therapy era, mortality rates subsequent to an ADE depend on
the speciﬁc diagnosis. The proposed classiﬁcation of ADEs may be useful in clinical end point trials, prognostic
studies, and patient management.
The reporting of unusual conditions, such as Kaposi
sarcoma and Pneumocystis jiroveci pneumonia (PCP),
among men who have sex with men signalledthearrival
of HIV in the early 1980s [1, 2]. A deﬁnition for the
new syndrome of AIDS was devised in 1985 [3]. The
case deﬁnition was developed by epidemiologists with
the aim of tracking the emerging epidemic. Changes to
this surveillance case deﬁnition were made in 1987 and
1993, when additional opportunistic infections were
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added to the list of AIDS-deﬁning events (ADEs) [4,
5]. Although the case deﬁnition of AIDS was never
intended for this purpose, researchers adopted AIDS as
an end point in clinical research, and clinicians used it
as a prognostic marker. Indeed, before the advent of
combination antiretroviral therapy (cART), patients
who received a diagnosis of AIDS had a poor median
survival of 12–18 months [6]. However, there was con-
siderable variation in the duration of survival, depend-
ing on the speciﬁc diagnosis [7] andtheCD4
+cellcount
at diagnosis [8].
In the era of cART, clinical trials have continued to
use AIDS as a marker of clinical disease progression
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[9–11], although the low incidence of ADEs meant that many
studies used changes in HIV load or CD4
+ cell count, rather
than the occurrence of AIDS or death, as their main end point.
Large cohort studies and collaborations of cohorts used AIDS
in prognostic models and risk scores to help clinicians, care
providers, and patients to assess short-term and medium-term
prognosis after initiating cART [12–14].
Studies that use AIDS as an end point or prognostic factor
make an implicit assumption that all ADEs have the same con-
sequence in terms of subsequent morbidity and mortality. To
our knowledge, no study to date has had sufﬁcient power to
examine the variation in subsequent mortality associated with
speciﬁc ADEs among patients receiving cART. We analyzed the
large database of the Antiretroviral Therapy Cohort Collabo-
ration (ART-CC) to determine the relative importance of dif-
ferent ADEs for subsequent mortality and to rank ADEs in
terms of their prognostic importanceforpatientsstartingcART.
METHODS
ART-CC. The ART-CC is a collaboration of cohort studies
from Europe and North America that was established in 2000
with the aim of describing the prognosis of antiretroviral-naive
patients starting cART. The study design has been described in
detail elsewhere [15]. In brief, prospective cohort studies were
eligible if they had enrolled at least 100 patients with HIV
infection aged 16 years who had not previously received an-
tiretroviraltreatmentandwhohadstartedantiretroviraltherapy
with a combination of at least 3 drugs, including nucleoside
reverse-transcriptase inhibitors, protease inhibitors, or non-
nucleoside reverse-transcriptase inhibitors, with a median du-
ration of follow-up of at least 1 year. Cohorts provided an-
onymized data on a predeﬁned set of demographic, laboratory,
and clinical variables, including age, sex, risk group, drugs in-
cluded in the cART regimen, CD4
+ cell count and viral load
at cART initiation and at 6 and 36 months, in addition to the
CD4
+ cell count before the diagnosis of an ADE (each CD4
+
cell count was measured within a maximum periodof6months
before the relevant time point).
Participating cohorts. Fifteen cohorts contributed data:
the AIDS Therapy Evaluation Project Netherlands (3903 pa-
tients); the Aquitaine Cohort (831 patients); the British Co-
lumbia Centre for Excellence in HIV/AIDS (764 patients); Col-
laborations in HIV Outcomes Research (924 patients); the
EuroSIDA study (92 centres across Europe, Argentina, and Is-
rael; 1315 patients); the Frankfurt HIV Cohort (1436 patients);
the French Hospital Database on HIV (13,758 patients); the
Italian Cohort of Antiretroviral-Naive Patients (2428 patients);
the Ko ¨ln/Bonn Cohort (406 patients); the Proyecto para la
Informatizacio ´n del Seguimento Clı ´nico-Epidemiolo ´gico de la
Infeccio ´n por HIV y SIDA (1851 patients); the Royal Free Hos-
pital Cohort (649 patients); the Southern Alberta Clinic (270
patients); the Swiss HIV Cohort Study (2275 patients); the
University of Alabama at Birmingham 1917 Clinic Cohort (485
patients); and the University of Washington HIV Cohort (322
patients). All cohorts have been approved by their local ethics
committees or institutional review boards, use standardized
methods of data collection, and schedule follow-up visits at
least once every 6 months.
Inclusion criteria and deﬁnitions. All antiretroviral-naive
patients with HIV infection who initiated cART before 31 De-
cember 2004 but who had not received a prior diagnosis of
AIDS were included in analyses. Patient selection and data ex-
traction were performed at the data centers of the participating
cohorts. Anonymized data were pooled and analyzed centrally.
ADEs were ascertained prospectively by use of the diagnostic
criteria outlined in the 1993 AIDS deﬁnition[5].Bothdeﬁnitive
and presumptive diagnoses were included in analyses. Type-
speciﬁc ADEs were combined into a single category; thus, cy-
tomegalovirus retinitis and cytomegalovirus infection of other
sites were combined into a single cytomegalovirus infection
category. Different types of non-Hodgkin’s lymphoma (e.g.,
Burkitt’s lymphoma, primary brain lymphoma, immunoblastic
lymphoma, and lymphoma of unknown histology) were also
combined into a single category. ADEs that occurred in !50
patients in the combined dataset were grouped togethertoform
a “rare ADEs” category and included coccidioidomycosis (1
diagnosis, 0 deaths), pulmonary candidiasis (15 diagnoses, 6
deaths), histoplasmosis (17 diagnoses, 4 deaths), invasive cer-
vical carcinoma (20 diagnoses, 3 deaths), isosporiasis (7 di-
agnoses, 0 deaths), salmonella septicemia (7 diagnoses, 2
deaths), unspeciﬁed Centers for Disease Control and Preven-
tion type C events (2 diagnoses, 1 death), unspeciﬁed tuber-
culosis (6 diagnoses, 1 death), and bacterial pneumonia (48
diagnoses, 5 deaths).
Statistical methods. Cox proportional hazards models,
stratiﬁed by cohort and adjusted for sex, risk group, age, CD4
+
cell count and viral load at cART initiation, cART regimen,
and date of cART initiation were used to estimate the mortality
hazard ratio (MHR) after each of the ADEs, compared with
the MHR in patients who had not experienced an ADE. Each
ADE was treated as a time-dependent covariate, and all ADEs
were included in the model simultaneously. The proportional
hazards assumption was tested, and there was no evidence of
nonproportionality ( ). Recurrences of the sameADE were P 1 .2
not included in analyses. Patients were followed up from the
date of cART initiation until death (of any cause). All analyses
were intent-to-treat, ignoring treatment interruptions or stop-
ping of antiretroviral therapy. Patients who remained alivewere
censored at their last visit plus 50% of the median timebetween
visits for each cohort. For example, if a cohort had a median
of 6 months between follow-up visits, patients who did not die
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Percentage of all patients 100 7.2
Age, median years (IQR) 36 (31–43) 37 (32–44)
Sex
Male 22,730 (71.9) 1729 (76.4)
Female 8890 (28.1) 533 (23.6)
Transmission risk group
Heterosexual sex 12,545 (39.7) 865 (38.2)
IDU 4786 (15.1) 421 (18.6)
Men who have sex with men 11,361 (35.9) 777 (34.4)
Other 2928 (9.3) 199 (8.8)





+ cell count, median cells/mL (IQR) 256 (145–384) 138 (45–275)
Baseline viral load, median log10 copies/mL (IQR) 4.84 (4.31–5.30) 5.16 (4.65–5.61)
No. of antiretroviral drugs received
3 26,163 (82.7) 1807 (79.9)
4 5457 (17.3) 455 (20.1)
Type of cART received
PI based 18,153 (57.4) 1551 (68.6)
NNRTI based 9765 (30.9) 494 (21.8)
NRTIs only 2937 (9.3) 150 (6.6)
Other 765 (2.4) 67 (3.0)
NOTE. Data are no. (%) of patients, unless otherwise indicated. cART, combination antiretroviral therapy; IDU,
injection drug use; IQR, interquartile range; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside
reverse-transcriptase inhibitor; PI, protease inhibitor.
ratios for each ADE were ranked, and bootstrapping was used
to derive 95% CIs for these ranks (on the basis of the 2.5th
and 97.5th percentiles of ranks in 1000 resampled datasets).
ADEs were split into 3 severity groups on the basis of these
ranks, and the adjusted MHRs (aMHRs) for mild, moderate,
and severe diagnoses were determined after additional adjust-
ment for the number of ADEs diagnosed as a time-dependant
covariate.
Patients starting cART may experience a rapid increase in
their CD4
+ cell count during the ﬁrst 6 months of therapy [16],
which will affect the subsequent risk of developing an ADE,
and ADEs developing within the ﬁrst 6 months of cART may
be caused by immune reconstitution syndrome[17].Therefore,
we performed an additional analysis to estimate the risk of
mortality following an ADE diagnosed after this initial period
of treatment. Follow-up was censored at 6 months after cART
initiation; patients with !6 months of follow-up were excluded,
and ADEs that occurred during the initial 6 months after cART
initiation were excluded. This analysiswasadjustedasdescribed
above and was additionally adjusted for the CD4
+ cell count
and viral load determined at 6 months after cART initiation.
Statistical analyses were performed using SAS, version 9.1
(SAS). Bootstrapping was performed using Stata software, ver-
sion 10.0 (StataCorp).
RESULTS
The characteristics of the 31,620 patients included in analyses
are shown in table 1. Over a median follow-up period of 43
months (interquartile range [IQR], 19–70months;117,986per-
son-years of follow-up), 1146 patients (3.6%) died; of these
patients, 377 died after an ADE. There were 2262 patients
(7.2%) who received diagnoses of 2880 distinct ADEs. A total
of 1745 (77.1%) of these 2262 patients received a diagnosis of
1 ADE during follow-up, 356 (15.7%) received diagnoses of 2
ADEs, 95 (4.2%) received diagnoses of 3 ADEs, and 22 (1.0%)
received diagnosesof4 ADEs.Themostcommonlydiagnosed
ADEs were esophageal candidiasis (360 diagnoses), Pneumo-
cystis jiroveci (carinii) pneumonia (322 diagnoses), Kaposi sar-
coma (308 diagnoses), pulmonary tuberculosis (257 diagnoses)
and non-Hodgkin’s lymphoma (225 diagnoses).
The CD4
+ cell count at the time of diagnosis of each ADE
(available for 2635 [91.5%] of the ADEs), was measured a
median of 4 days before the ADE (IQR, 0–32 days).Themedian
CD4
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Figure 1. Median patient CD4
+ cell count at diagnosis (interquartile range [IQR]) for each type of AIDS-deﬁning event (ADE). COC, cryptococcosis;
CMV, cytomegalovirus infection; DEM; AIDS dementia complex; ESO, esophageal candidiasis; HSD, herpes simplex disease; KSA, Kaposi’s sarcoma;
MAC, disseminated mycobacterial disease; NHL, non-Hodgkin’s lymphoma (including primary brain lymphoma); OTH, all ADEs that occurred in !50
patients; PCP, Pneumocystis jiroveci (carinii) pneumonia; PML, progressive multifocal leukoencephalopathy; SPO; cryptosporidiosis; TBC; pulmonary
tuberculosis; TEX, extrapulmonary tuberculosis; TOX, cerebral toxoplasmosis; WAS, HIV wasting syndrome.
Figure 2. AIDS-deﬁning events (ADEs) stratiﬁed by patient viral load at diagnosis of each type of ADE. COC, cryptococcosis; CMV, cytomegalovirus
infection; DEM; AIDS dementia complex; ESO, esophageal candidiasis; HSD, herpes simplex disease; KSA, Kaposi’s sarcoma; MAC, disseminated
mycobacterial disease; NHL, non-Hodgkin’s lymphoma (including primary brain lymphoma); OTH, allADEs that occurredin !50patients;PCP,Pneumocystis
jiroveci (carinii) pneumonia; PML, progressive multifocal leukoencephalopathy; SPO; cryptosporidiosis; TBC; pulmonary tuberculosis;TEX,extrapulmonary
tuberculosis; TOX, cerebral toxoplasmosis; WAS, HIV wasting syndrome.
(33.8%) of the 2635 ADEs with available data occurring at a
CD4
+ cell count of 50 cells/mL, 924 (35.1%) occurring at 51–
200 cells/mL, 412 (15.6%) occurring at 201–350 cells, 189
(7.2%) occurringat351–500cells/mL,and219(8.3%)occurring
at 1500 cells/mL. Figure 1 illustrates the CD4
+ cell counts at
diagnosis, stratiﬁed by the type of ADE. Non-Hodgkin’s lym-
phoma occurred at the highest median CD4
+ cell count (204
cells/mL), with only 34 (16.4%) of the diagnoses made in pa-
tients with CD4
+ cell counts 50 cells/mL. The viral load at
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Figure 3. Adjusted mortality hazard associated with each type of AIDS-deﬁning event (ADE) after initiation of combination antiretroviral therapy
(cART). The model was stratiﬁed by cohort and adjusted for age, sex, exposure group, number of drugs in the initial cART regimen, type of cART
regimen, date of cART initiation, and patient CD4
+ cell count and viral load at cART initiation. COC, cryptococcosis; CMV, cytomegalovirus infection;
DEM; AIDS dementia complex; ESO, esophageal candidiasis; HSD, herpes simplex disease; KSA, Kaposi’s sarcoma; MAC, disseminated mycobacterial
disease; NHL, non-Hodgkin’s lymphoma (including primary brain lymphoma); OTH, all ADEs that occurred in !50 patients; PCP, Pneumocystis jiroveci
(carinii) pneumonia; PML, progressive multifocal leukoencephalopathy; SPO; cryptosporidiosis; TBC; pulmonary tuberculosis; TEX, extrapulmonary tu-
berculosis; TOX, cerebral toxoplasmosis; WAS, HIV wasting syndrome.
Table 2. Ranking and classiﬁcation of AIDS-deﬁning events (ADEs) ac-
cording to severity (impact on subsequent mortality) in antiretroviral-naive






Non-Hodgkin’s lymphoma 16 (15–16) Severe
Progressive multifocal leukoencephalopathy 15 (13–16) Severe
Cryptococcosis 14 (8–15) Moderate
Cerebral toxoplasmosis 12 (6–14) Moderate
Rare ADE
a 12 (8–14) Moderate
AIDS dementia complex 11 (6–14) Moderate
Disseminated Mycobacterium avium disease 11 (6–14) Moderate
HIV wasting syndrome 8 (2–13) Mild
Pulmonary tuberculosis 7 (3–12) Mild
Pneumocystis jiroveci (carinii) pneumonia 7 (3–11) Mild
Extrapulmonary tuberculosis 5 (1–10) Mild
Esophageal candidiasis 5 (2–9) Mild
Cryptosporidiosis 4 (1–12) Mild
Cytomegalovirus infection 4 (1–9) Mild
Kaposi sarcoma 3 (1–8) Mild
Herpes simplex disease 1 (1–8) Mild
NOTE. Ranking is based on multivariate hazard ratios from bootstrap analyses (np
). 1000
a Rare ADEs were deﬁned as those that occurred in !50 patients and included coccid-
ioidomycosis, pulmonary candidiasis, extrapulmonary pneumocystis disease, histoplas-
mosis, invasive cervical carcinoma, isosporiasis, salmonella septicaemia, and bacterial
pneumonia.
was measured a median of 35 days before the ADE (IQR, 6–
77 days). In total, 285 (17.3%) of the 1649 ADEs with available
data occurred at viral loads !500 copies/mL, 154 (9.3%) oc-
curred at 500–9999 copies/mL, and 1210 (73.4%) occurred at
10000 copies/mL. The distribution of the ADEs, stratiﬁed by
viral load category at diagnosis, is shown in ﬁgure 2.
The median time from initiation of cART to diagnosis of
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Table 3. Number of AIDS-deﬁning events (ADEs) and deaths overall and within the ﬁrst 6 months after initiation of combination
antiretroviral therapy (cART) and adjusted mortality hazard ratios (aMHRs) associated with ADEs diagnosed after 6 months of therapy



















Non-Hodgkin’s lymphoma 225 (7.8) 86 88 (40.4) 31 11.62 (8.69–15.54)
Progressive multifocal leukoencephalopathy 80 (2.8) 27 44 (55.0) 12 9.41 (5.90–15.02)
Cryptococcosis 66 (2.3) 14 30 (45.4) 6 4.33 (2.11–8.90)
Rare ADE
b 168 (5.8) 32 76 (45.2) 11 2.94 (1.61–5.40)
Cerebral toxoplasmosis 177 (6.2) 41 69 (39.0) 12 4.11 (2.78–6.08)
Disseminated Mycobacterium avium disease 177 (6.2) 45 107 (61.6) 21 2.68 (1.79–4.02)
AIDS dementia complex 137 (4.8) 41 69 (50.4) 20 3.60 (2.39–5.43)
HIV wasting syndrome 134 (4.7) 29 48 (35.8) 13 2.89 (1.73–4.83)
Pulmonary tuberculosis 257 (8.9) 30 116 (45.1) 11 2.39 (1.46–3.89)
Pneumocystis jiroveci (carinii) pneumonia 322 (11.2) 57 127 (39.4) 15 2.36 (1.66–3.36)
Extrapulmonary tuberculosis 203 (7.1) 21 93 (45.8) 6 1.37 (0.75–2.48)
Esophageal candidiasis 360 (12.5) 69 111 (30.8) 16 1.84 (1.32–2.56)
Cytomegalovirus infection 122 (4.2) 25 66 (54.1) 8 1.60 (0.99–2.61)
Cryptosporidiosis 60 (2.1) 8 20 (33.3) 1 2.14 (0.93–4.94)
Kaposi sarcoma 308 (10.7) 33 176 (57.1) 16 1.33 (0.84–2.12)
Herpes simplex disease 84 (2.9) 9 36 (42.9) 3 0.97 (0.44–2.14)
a Comparing the hazard of death after each of the ADEs with the hazard of death among patients who have not experienced an ADE. Multivariate Cox
proportional hazards models were stratiﬁed by center and adjusted for sex, exposure group, age, CD4
+ cell count and viral load at initiation of cART, type of
regimen initiated, and date of initiation.
b Rare ADEs were deﬁned as those that occurred in !50 patients and included coccidioidomycosis, pulmonary candidiasis, extrapulmonary pneumocystis
disease, histoplasmosis, invasive cervical carcinoma, isosporiasis, salmonella septicaemia, and bacterial pneumonia.
(11.0%), 405 (14.1%), 495 (17.2%) and 382 (13.3%) of the
ADEs occurred 6 months, 6–12 months, 12–24 months, 24–
48 months, and 148 months after cART initiation, respectively.
The median CD4
+ cell count at diagnosis for ADEs that oc-
curred 6 months after cART initiation (based on data avail-
able for 1269 [48.2%] of the ADEs) was slightly lower (86 cells/
mL; IQR, 30–204 cells/mL) than that for ADEs that occurred
after 6 months (129 cells/mL; IQR, 35–288 cells//mL). The ma-
jority of ADEs that were diagnosed within 6 months after cART
initiation occurred in patients with viral loads 10,000 copies/
mL (1048 [83.3%] of 1258 ADEs with data), whereas almost
one-half of the ADEs diagnosed after 6 months occurred in
patients with viral loads of !500 copies/mL (176 [45.0%] of
391 ADEs with data).
The aMHR associated with the diagnosis of any ADE was
3.45 (95% CI, 2.75–4.32). Figure 3 illustrates the aMHR as-
sociated with each ADE, ordered from the least severe to the
most severe. At one end of the spectrum, there was little evi-
dence for an increased risk of death associated with recurrent
herpes simplex disease, with an aMHR of 1.09 (95% CI, 0.53–
2.25). At the other end of the spectrum, a diagnosis of non-
Hodgkin’s lymphoma was associated with an 18-fold increase
in mortality (aMHR, 17.59; 95% CI, 13.84–22.35), whereas
progressivemultifocalleukoencephalopathywasassociatedwith
a 10-fold increase in mortality (aMHR, 10.00; 95% CI, 6.70–
14.92). Cryptococcosis, cerebral toxoplasmosis, the group of
rare ADEs, AIDS dementia complex, and disseminated Myco-
bacterium avium complex were the next most serious events,
with aMHRs of 4–7. The ranks of the aMHR for each ADE,
with bootstrapped 95% CIs, are shown in table 2. As would
be expected, there was considerable sampling variability in the
ranks, but 3 groups of ADEs could be identiﬁed: severe (non-
Hodgkin’s lymphoma and progressive multifocal leukoenceph-
alopathy), moderate (disseminated M. avium complex, AIDS
dementia complex, rare ADEs, toxoplasmosis, and cryptococ-
cosis), and mild (all other ADEs). The aMHR associated with
any severe ADE was 7.26 (95% CI, 5.55–9.48), the aMHR as-
sociated with a moderate ADE was 2.35 (95% CI, 1.76–3.13),
and the aMHR associated with a mild ADE was 1.47 (95% CI,
1.08–2.00).
There were some differences between the ADEs in terms of
the proportion of diagnoses that occurred within the initial 6
months of cART (table 3), ranging from 30.8% for esophageal
candidiasis to 61.6% for disseminated M. avium complex. Table
3 also presents the aMHR after the initial 6 months of cART,
adjusted additionally for the CD4
+ cell count and viral load at
6 months after cART initiation and taking account of the initial
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reduced number of ADEs, patterns of mortality are similar to
those seen in ﬁgure 3 and table 2.
DISCUSSION
AIDS was ﬁrst deﬁned in the 1980s for surveillance purposes.
However, in the era of cART, AIDS continues to be used as a
composite outcome in clinicalresearchandaprognosticmarker
in routine clinical care. Clinical trials that use outcome data
assume that all ADEs have similar impacts on survival. The
analyses presented here, which are based on 131,000 patients
and almost 3000 ADEs, demonstrate substantial variation both
in the median CD4
+ cell count at diagnosis of different ADEs
and in the relative hazard of death after the diagnosis. We
identiﬁed 3 groups of ADEs, based on the prognosis after di-
agnosis: severe ADEs, which are associated with a substantial
increase in the risk of death; ADEs with a moderate impact on
subsequent mortality; and mild ADEs, which have a relatively
small inﬂuence on subsequent mortality.
The large size of the collaborative database, which includes
patients treated in different settings in countries from Europe
and North America, is a strength of this study. ADEs were
ranked before the widespread introduction of cART [18, 19],
but to our knowledge, this is the ﬁrst study with sufﬁcient
power to enable most ADEs to be compared only among pa-
tients who have started cART. Previous studies that have con-
sidered survival after an initial ADE included only those pa-
tients who received a diagnosis of an ADE and included a
signiﬁcant proportion of patients who received a diagnosis of
AIDS between 1990 and 1995 (when the widespread introduc-
tion of cART occurred) [20–22] or who received a diagnosis
before cART became widely available [23]. This analysis thus
makes an important contribution to deﬁning the prognosis of
patients who developed an ADE while receiving cART. Such
information is of obvious importance to patients and their
health care providers and is required to monitor and predict
the progress of the epidemic, as well as to plan health services
in the era of cART [24].
The initial immunologic response to cART is important for
predicting prognosis after cART initiation [25]; in this study,
ADEs diagnosed within 6 months after cART initiationtypically
occurred at slightly lower CD4
+ cell counts than did ADEs that
were diagnosed 16 months after cART initiation, which is con-
sistent with the recovery of immune function subsequent to
starting cART. The so-called immune reconstitution inﬂam-
matory syndrome occurs when the immune system begins to
respond to preexisting opportunistic disorders that were pre-
sent before initiation of antiretroviral therapy [26]. We have
also presented the aMHRs, both from the time of cART ini-
tiation and from after the initial 6 months of therapy. In dif-
ferent circumstances, it may be appropriate to use either the
post-cART initiation data (which represents a combination of
immunocompromise, disease severity, and treatment effective-
ness) or the pre-cART initiation data (which generally reﬂects
untreated or poorly treated ADEs and, therefore, represents
immunocompromise more speciﬁcally).
The use of composite end points, such as AIDS, in clinical
trials can be advantageous: combined end points result in
higher event rates, which translate into a smaller sample size,
shorter trial duration, or greater precision of estimates; disease
progression can then be measured either as progression to any
ADE or progression to a more serious ADE. Composite end
points could also be used as a predeﬁned secondary end point
or incorporated into sensitivity analyses. However, the validity
of composite end points rests on the assumption that patients
and clinicians attach a similar importance to the different com-
ponents and that these components will be affected in similar
ways by interventions [27–29]. Combining different ADEs as
a single event means that important prognostic information is
lost. Although the groupings proposed here were assigned post
hoc, our results conﬁrm the ﬁndings of previous smallerstudies
that integrated the severity of an ADE into ranking systems
[30, 31], rather than treating all ADEs equally. It is also worth
noting that the ranking of the diseases in the cART treatment
era matches well with the ranking of diagnoses made before
the widespread introduction of cART [32]. Although our clas-
siﬁcation by severity overcomes some of the drawbacks of the
composite end point AIDS, what we propose are 3 composite
outcomes that include a varying number of ADEs that have a
similar impact on mortality. From the perspective of patients,
ADEs continue to differ in important ways within the same
prognostic group. For example, within the group of ADEs as-
sociated with moderately increased risk of death, AIDS de-
mentia complex may well be judged to be more severe than
the other events in this group. Similarly, it seems unlikely that
the biologically diverse conditions within each group will be
affected in the same way by antiretroviral drugs or other
interventions.
There are some limitations to this study. Patients who died
after an ADE may not have died of causes that were directly
associated with the ADE that was diagnosed. The ART-CC is
currently collecting information on causes of death for all pa-
tients and is using this information to categorizecausesofdeath
when possible. Preliminary data suggest that, of those patients
whose cause of death could be classiﬁed, ∼40% died of AIDS.
The major non-AIDS causes of death among these patients
were non–AIDS–deﬁning malignancies, violent causes (includ-
ing suicide and substance abuse), heart disease, and liver dis-
ease. Detailed information on the causes of death among ART-
CC patients will be presented in a separate article.
The ART-CC does not collect information on coinfections,
such as hepatitis, cardiovascular disease, non–AIDS-deﬁning
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[33–35]. We were not able to adjust for immunodeﬁciency or
treatment interruptions throughout the follow-up period;how-
ever, the risk of death among HIV-infected patients increases
as the CD4
+ cell count decreases [36, 37]. Results were similar
when the initial response to cART was taken into account by
adjusting for CD4
+ cell count and HIV RNA level at 6 months
after initiation of therapy. The data were from a number of
cohorts, and there is some variation in the ascertainment of
ADEs. This analysis focused on the ﬁrst ADE experienced after
cART initiation, and the rankings could varyifrecurrenceswere
included. Finally, despite the large size of the collaborative co-
hort, the number of some types of ADEs was too small to allow
separate analyses of these events.
In conclusion, in the cART era, mortality rates after an ADE
depend on the speciﬁc ADE diagnosed, and not all ADEs are
created equal. The severity of ADEs should be considered in
clinical trials with clinical end points and in future prognostic
models, as well as in patient management. Similar studies are
required in lower-income settings, where cART is increasingly
used but where outcomes differ from those observed in in-
dustrialized settings [38].
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